144 related articles for article (PubMed ID: 31721120)
1. In Vivo Bioluminescent Monitoring of Parasites in BALB/c Mouse Models of Cutaneous Leishmaniasis Drug Discovery.
Caridha D; Leed S; Cawlfield A
Methods Mol Biol; 2020; 2081():81-106. PubMed ID: 31721120
[TBL] [Abstract][Full Text] [Related]
2. Use of Optical Imaging Technology in the Validation of a New, Rapid, Cost-Effective Drug Screen as Part of a Tiered
Caridha D; Parriot S; Hudson TH; Lang T; Ngundam F; Leed S; Sena J; Harris M; O'Neil M; Sciotti R; Read L; Lecoeur H; Hickman M; Grogl M
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137819
[TBL] [Abstract][Full Text] [Related]
3. Use of In Vivo Imaging System Technology in Leishmania major BALB/c Mouse Ear Infection Studies.
Cawlfield A; Vesely B; Ngundam F; Butler K; Nugent D; Rowland T; Caridha D
J Med Entomol; 2018 Feb; 55(2):429-435. PubMed ID: 29253231
[TBL] [Abstract][Full Text] [Related]
4. Appraisal of a Leishmania major strain stably expressing mCherry fluorescent protein for both in vitro and in vivo studies of potential drugs and vaccine against cutaneous leishmaniasis.
Calvo-Álvarez E; Guerrero NA; Alvarez-Velilla R; Prada CF; Requena JM; Punzón C; Llamas MÁ; Arévalo FJ; Rivas L; Fresno M; Pérez-Pertejo Y; Balaña-Fouce R; Reguera RM
PLoS Negl Trop Dis; 2012; 6(11):e1927. PubMed ID: 23209866
[TBL] [Abstract][Full Text] [Related]
5. Study of the
Azadi R; Alipour-Talesh G; Yazdanpanah MJ; Alavizadeh SH; Maleki M; Banihashemi M; Jaafari MR
J Vector Borne Dis; 2020; 57(1):78-84. PubMed ID: 33818460
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of NanoLuc, RedLuc and Luc2 as bioluminescent reporters in a cutaneous leishmaniasis model.
Agostino VS; Trinconi CM; Galuppo MK; Price H; Uliana SRB
Acta Trop; 2020 Jun; 206():105444. PubMed ID: 32173317
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Infectivity Assessment by Drug Susceptibility Comparison of Recombinant Leishmania major Expressing Enhanced Green Fluorescent Protein or EGFP-Luciferase Fused Genes with Wild-Type Parasite.
Sadeghi S; Seyed N; Etemadzadeh MH; Abediankenari S; Rafati S; Taheri T
Korean J Parasitol; 2015 Aug; 53(4):385-94. PubMed ID: 26323836
[TBL] [Abstract][Full Text] [Related]
8. Direct comparison of the efficacy and safety of oral treatments with oleylphosphocholine (OlPC) and miltefosine in a mouse model of L. major cutaneous leishmaniasis.
Fortin A; Caridha DP; Leed S; Ngundam F; Sena J; Bosschaerts T; Parriott S; Hickman MR; Hudson TH; Grogl M
PLoS Negl Trop Dis; 2014 Sep; 8(9):e3144. PubMed ID: 25210745
[TBL] [Abstract][Full Text] [Related]
9. Development of a target-free high-throughput screening platform for the discovery of antileishmanial compounds.
Corman HN; Shoue DA; Norris-Mullins B; Melancon BJ; Morales MA; McDowell MA
Int J Antimicrob Agents; 2019 Oct; 54(4):496-501. PubMed ID: 31323307
[TBL] [Abstract][Full Text] [Related]
10. In vivo imaging of transgenic Leishmania parasites in a live host.
Thalhofer CJ; Graff JW; Love-Homan L; Hickerson SM; Craft N; Beverley SM; Wilson ME
J Vis Exp; 2010 Jul; (41):. PubMed ID: 20689512
[TBL] [Abstract][Full Text] [Related]
11. Combination of paromomycin plus human anti-TNF-α antibodies to control the local inflammatory response in BALB/ mice with cutaneous leishmaniasis lesions.
Schwartz J; Moreno E; Calvo A; Blanco L; Fernández-Rubio C; Sanmartín C; Nguewa P; Irache JM; Larrea E; Espuelas S
J Dermatol Sci; 2018 Oct; 92(1):78-88. PubMed ID: 30037731
[TBL] [Abstract][Full Text] [Related]
12. A Review: The Current In Vivo Models for the Discovery and Utility of New Anti-leishmanial Drugs Targeting Cutaneous Leishmaniasis.
Mears ER; Modabber F; Don R; Johnson GE
PLoS Negl Trop Dis; 2015; 9(9):e0003889. PubMed ID: 26334763
[TBL] [Abstract][Full Text] [Related]
13. Parasite burden in Leishmania (Leishmania) amazonensis-infected mice: validation of luciferase as a quantitative tool.
Reimão JQ; Trinconi CT; Yokoyama-Yasunaka JK; Miguel DC; Kalil SP; Uliana SR
J Microbiol Methods; 2013 May; 93(2):95-101. PubMed ID: 23466934
[TBL] [Abstract][Full Text] [Related]
14. Generation of stable L. major(+EGFP-LUC) and simultaneous comparison between EGFP and luciferase sensitivity.
Taheri T; Saberi Nik H; Seyed N; Doustdari F; Etemadzadeh MH; Torkashvand F; Rafati S
Exp Parasitol; 2015 Mar; 150():44-55. PubMed ID: 25637784
[TBL] [Abstract][Full Text] [Related]
15. Optimization of topical therapy for Leishmania major localized cutaneous leishmaniasis using a reliable C57BL/6 Model.
Lecoeur H; Buffet P; Morizot G; Goyard S; Guigon G; Milon G; Lang T
PLoS Negl Trop Dis; 2007 Nov; 1(2):e34. PubMed ID: 18060082
[TBL] [Abstract][Full Text] [Related]
16. Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis.
Caridha D; Vesely B; van Bocxlaer K; Arana B; Mowbray CE; Rafati S; Uliana S; Reguera R; Kreishman-Deitrick M; Sciotti R; Buffet P; Croft SL
Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():106-117. PubMed ID: 31320296
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution and
Iman M; Huang Z; Alavizadeh SH; Szoka FC; Jaafari MR
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630182
[TBL] [Abstract][Full Text] [Related]
18. Leishmania major: activity of tamoxifen against experimental cutaneous leishmaniasis.
Eissa MM; Amer EI; El Sawy SM
Exp Parasitol; 2011 Aug; 128(4):382-90. PubMed ID: 21620834
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of total phenolic fraction derived from extra virgin olive oil for its antileishmanial activity.
Koutsoni OS; Karampetsou K; Kyriazis ID; Stathopoulos P; Aligiannis N; Halabalaki M; Skaltsounis LA; Dotsika E
Phytomedicine; 2018 Aug; 47():143-150. PubMed ID: 30166099
[TBL] [Abstract][Full Text] [Related]
20. In-vitro and in-vivo comparative effects of the spring and autumn-harvested Artemisia aucheri Bioss extracts on Leishmania major.
KarimiPourSaryazdi A; Ghaffarifar F; Dalimi A; Dayer MS
J Ethnopharmacol; 2020 Jul; 257():112910. PubMed ID: 32344159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
